CN105324362B - Ido抑制剂 - Google Patents
Ido抑制剂 Download PDFInfo
- Publication number
- CN105324362B CN105324362B CN201480028214.8A CN201480028214A CN105324362B CN 105324362 B CN105324362 B CN 105324362B CN 201480028214 A CN201480028214 A CN 201480028214A CN 105324362 B CN105324362 B CN 105324362B
- Authority
- CN
- China
- Prior art keywords
- phenyl
- diisobutylamino
- ureido
- acid
- butanoic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*(C)(*)[N+](*(C)(C)C1=*C(C(*)(*)C(*)(*)*)=C*CCC=C1*)[O-] Chemical compound C*(C)(*)[N+](*(C)(C)C1=*C(C(*)(*)C(*)(*)*)=C*CCC=C1*)[O-] 0.000 description 3
- PJIOEUPDHUGTBB-CUXHJGIESA-N C/C=C(\C(\F)=C/CC#C)/N Chemical compound C/C=C(\C(\F)=C/CC#C)/N PJIOEUPDHUGTBB-CUXHJGIESA-N 0.000 description 1
- XZGLNCKSNVGDNX-UHFFFAOYSA-N Cc1nnn[nH]1 Chemical compound Cc1nnn[nH]1 XZGLNCKSNVGDNX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
- C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Epoxy Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361787939P | 2013-03-15 | 2013-03-15 | |
| US61/787,939 | 2013-03-15 | ||
| PCT/US2014/023877 WO2014150646A1 (en) | 2013-03-15 | 2014-03-12 | Ido inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105324362A CN105324362A (zh) | 2016-02-10 |
| CN105324362B true CN105324362B (zh) | 2017-05-24 |
Family
ID=50391513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480028214.8A Expired - Fee Related CN105324362B (zh) | 2013-03-15 | 2014-03-12 | Ido抑制剂 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9624188B2 (enExample) |
| EP (1) | EP2970114B1 (enExample) |
| JP (1) | JP6313415B2 (enExample) |
| KR (1) | KR20150129010A (enExample) |
| CN (1) | CN105324362B (enExample) |
| AU (1) | AU2014235816B2 (enExample) |
| BR (1) | BR112015022462A8 (enExample) |
| CA (1) | CA2907178A1 (enExample) |
| EA (1) | EA028424B1 (enExample) |
| ES (1) | ES2733546T3 (enExample) |
| HK (1) | HK1220442A1 (enExample) |
| IL (1) | IL241321A0 (enExample) |
| MA (1) | MA38483A1 (enExample) |
| MX (1) | MX2015012056A (enExample) |
| PE (1) | PE20151594A1 (enExample) |
| PH (1) | PH12015502028A1 (enExample) |
| SG (1) | SG11201506920QA (enExample) |
| WO (1) | WO2014150646A1 (enExample) |
| ZA (1) | ZA201506796B (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| WO2014150677A1 (en) * | 2013-03-15 | 2014-09-25 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase (ido) |
| WO2015002918A1 (en) | 2013-07-01 | 2015-01-08 | Bristol-Myers Squibb Company | Ido inhibitors |
| US9895330B2 (en) * | 2013-07-11 | 2018-02-20 | Bristol-Myers Squibb Company | IDO inhibitors |
| KR20170129902A (ko) | 2015-03-23 | 2017-11-27 | 조운스 테라퓨틱스, 인크. | Icos에 대한 항체 |
| AU2016242978A1 (en) * | 2015-04-03 | 2017-11-23 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer |
| MX2017015923A (es) * | 2015-06-26 | 2018-04-20 | Squibb Bristol Myers Co | Inhibidores de indolamina-2,3-dioxigenasa (ido). |
| CN107921087A (zh) | 2015-07-16 | 2018-04-17 | 百欧肯治疗有限公司 | 治疗癌症的组合物及方法 |
| CA3132620C (en) | 2015-07-24 | 2024-03-05 | Lumos Pharma, Inc. | Salts and prodrugs of 1-methyl-d-tryptophan |
| KR20180054827A (ko) * | 2015-09-24 | 2018-05-24 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 인돌아민 2,3-디옥시게나제의 조절제 |
| JP6971239B2 (ja) * | 2015-10-05 | 2021-11-24 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | グルタミナーゼ阻害剤とイムノオンコロジー薬剤との併用療法 |
| KR20180066236A (ko) | 2015-10-22 | 2018-06-18 | 조운스 테라퓨틱스, 인크. | Icos 발현을 계측하기 위한 유전자 특질 |
| CA3012133A1 (en) | 2016-02-09 | 2017-08-17 | Inventisbio Inc. | Inhibitor of indoleamine-2,3-dioxygenase (ido) |
| JP7066186B2 (ja) | 2016-02-19 | 2022-05-13 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 肥満の処置のための方法及び医薬組成物 |
| US11096930B2 (en) * | 2016-04-29 | 2021-08-24 | Merck Sharp & Dohme Corp. | Substituted imidazopyridine compounds as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan-2,3-dioxygenase |
| EP3455220A1 (en) | 2016-05-12 | 2019-03-20 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of indoleamine 2,3-dioxygenase |
| JOP20170131B1 (ar) * | 2016-06-10 | 2021-08-17 | Lilly Co Eli | مركبات 1-تيترا هيدروبيرانييل كاربونيل -2،3-ديهيدرو -1 h- اندول لعلاج السرطان |
| EP3505517A4 (en) * | 2016-08-23 | 2020-01-15 | Beijing InnoCare Pharma Tech Co., Ltd. | Fused heterocyclic derivative, preparation method therefor and medical use thereof |
| US10882856B2 (en) | 2016-09-24 | 2021-01-05 | Beigene, Ltd. | 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases |
| WO2018071873A2 (en) | 2016-10-13 | 2018-04-19 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
| HRP20211703T1 (hr) | 2016-11-02 | 2022-02-04 | Jounce Therapeutics, Inc. | Protutijela protiv pd-1 i njihova upotreba |
| CA3042698A1 (en) | 2016-11-04 | 2018-05-11 | Aximmune, Inc. | Beta-alethine, immune modulators, and uses thereof |
| US10899754B2 (en) | 2016-12-20 | 2021-01-26 | Glaxosmithkline Intellectual Property Development Limited | Modulators of indoleamine 2,3-dioxygenase |
| NZ754364A (en) | 2016-12-22 | 2023-04-28 | Calithera Biosciences Inc | Compositions and methods for inhibiting arginase activity |
| CA3047002A1 (en) | 2017-01-17 | 2018-07-26 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
| WO2018187191A1 (en) | 2017-04-03 | 2018-10-11 | Jounce Therapeutics, Inc | Compositions and methods for the treatment of cancer |
| WO2019074748A1 (en) * | 2017-10-09 | 2019-04-18 | Merck Sharp & Dohme Corp. | NOVEL SUBSTITUTED PHENYL-OXETANE AND PHENYLTETRAHYDROFURAN COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) |
| CN109836356B (zh) * | 2017-11-24 | 2022-03-08 | 沈阳化工研究院有限公司 | 一种芳甲醚衍生物及其应用 |
| JP7391868B2 (ja) | 2017-12-22 | 2023-12-05 | ジョウンセ セラピューティクス， インク． | Ｌｉｌｒｂ２に対する抗体 |
| US11813280B2 (en) | 2018-01-05 | 2023-11-14 | Dicerna Pharmaceuticals, Inc. | Reducing beta-catenin and IDO expression to potentiate immunotherapy |
| US11447449B2 (en) | 2018-01-05 | 2022-09-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| EP3793598A1 (en) | 2018-05-14 | 2021-03-24 | Jounce Therapeutics, Inc. | Methods of treating cancer |
| US11046649B2 (en) | 2018-07-17 | 2021-06-29 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
| US12145927B2 (en) | 2018-07-23 | 2024-11-19 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| WO2020023355A1 (en) | 2018-07-23 | 2020-01-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| WO2020081905A1 (en) | 2018-10-18 | 2020-04-23 | Jounce Therapeutics, Inc | Methods for treating cancer |
| US20210380942A1 (en) | 2018-10-24 | 2021-12-09 | Jounce Therapeutics, Inc. | Methods and compositions for the treatment of cancer and infectious diseases |
| US20210355222A1 (en) | 2018-10-26 | 2021-11-18 | Jounce Therapeutics, Inc. | Methods of Treating Cancer |
| US20220135682A1 (en) | 2019-03-11 | 2022-05-05 | Jounce Therapeutics, Inc. | Anti-ICOS Antibodies for the Treatment of Cancer |
| US20220378909A1 (en) | 2019-11-05 | 2022-12-01 | Jounce Therapeutics, Inc. | Methods of Treating Cancer with Anti-PD-1 Antibodies |
| WO2021096542A1 (en) | 2019-11-12 | 2021-05-20 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing ido antagonist prodrugs useful in the treatment of cancer and methods thereof |
| WO2021102618A1 (en) | 2019-11-25 | 2021-06-03 | InventisBio Co., Ltd. | Novel salts of indoleamine 2,3-dioxygenase inhibitors |
| EP4090771A1 (en) | 2020-01-13 | 2022-11-23 | Jounce Therapeutics, Inc. | Methods for the treatment of cancer |
| CN111153846B (zh) * | 2020-01-17 | 2021-08-31 | 中国药科大学 | 吡咯类化合物、其制备方法和药物组合物与用途 |
| IL295023A (en) | 2020-02-14 | 2022-09-01 | Jounce Therapeutics Inc | Antibodies and fusion proteins that bind to ccr8 and their uses |
| US11839659B2 (en) | 2020-07-02 | 2023-12-12 | Northwestern University | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein |
| EP4301358A2 (en) | 2021-03-05 | 2024-01-10 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
| EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
| WO2023235699A1 (en) | 2022-05-31 | 2023-12-07 | Jounce Therapeutics, Inc. | Antibodies to lilrb4 and uses thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002046146A1 (fr) * | 2000-12-05 | 2002-06-13 | Kyorin Pharmaceutical Co., Ltd. | Derives d'acide carboxylique substitues |
| CN1354742A (zh) * | 1999-06-09 | 2002-06-19 | 杏林制药株式会社 | 人过氧化物酶体增殖剂活化受体(PPAR)a激动剂——取代苯基丙酸衍生物 |
| CN102083429A (zh) * | 2008-04-24 | 2011-06-01 | 新联基因股份公司 | Ido抑制剂 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5447957A (en) * | 1994-06-02 | 1995-09-05 | Smithkline Beecham Corp. | Anti-inflammatory compounds |
| AU2003273179A1 (en) | 2002-05-10 | 2003-12-12 | Bristol-Myers Squibb Company | 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors |
| US20040034038A1 (en) * | 2002-08-13 | 2004-02-19 | Goaquan Li | Urea kinase inhibitors |
| US7056925B2 (en) * | 2002-08-13 | 2006-06-06 | Abbott Laboratories | Urea kinase inhibitors |
| US7388021B2 (en) * | 2004-05-12 | 2008-06-17 | Bristol Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| AU2005302669A1 (en) * | 2004-10-27 | 2006-05-11 | Neurogen Corporation | Diaryl ureas as CB1 antagonists |
| GB0613674D0 (en) * | 2006-07-10 | 2006-08-16 | Proskelia Sas | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor |
| WO2014150677A1 (en) | 2013-03-15 | 2014-09-25 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase (ido) |
-
2014
- 2014-03-12 MA MA38483A patent/MA38483A1/fr unknown
- 2014-03-12 BR BR112015022462A patent/BR112015022462A8/pt not_active Application Discontinuation
- 2014-03-12 SG SG11201506920QA patent/SG11201506920QA/en unknown
- 2014-03-12 EA EA201591823A patent/EA028424B1/ru not_active IP Right Cessation
- 2014-03-12 ES ES14714106T patent/ES2733546T3/es active Active
- 2014-03-12 KR KR1020157029305A patent/KR20150129010A/ko not_active Ceased
- 2014-03-12 HK HK16108593.6A patent/HK1220442A1/zh unknown
- 2014-03-12 CA CA2907178A patent/CA2907178A1/en not_active Abandoned
- 2014-03-12 EP EP14714106.3A patent/EP2970114B1/en active Active
- 2014-03-12 PE PE2015001950A patent/PE20151594A1/es not_active Application Discontinuation
- 2014-03-12 MX MX2015012056A patent/MX2015012056A/es unknown
- 2014-03-12 WO PCT/US2014/023877 patent/WO2014150646A1/en not_active Ceased
- 2014-03-12 AU AU2014235816A patent/AU2014235816B2/en not_active Ceased
- 2014-03-12 JP JP2016501372A patent/JP6313415B2/ja active Active
- 2014-03-12 CN CN201480028214.8A patent/CN105324362B/zh not_active Expired - Fee Related
- 2014-03-12 US US14/775,976 patent/US9624188B2/en active Active
-
2015
- 2015-09-08 IL IL241321A patent/IL241321A0/en unknown
- 2015-09-10 PH PH12015502028A patent/PH12015502028A1/en unknown
- 2015-09-14 ZA ZA2015/06796A patent/ZA201506796B/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1354742A (zh) * | 1999-06-09 | 2002-06-19 | 杏林制药株式会社 | 人过氧化物酶体增殖剂活化受体(PPAR)a激动剂——取代苯基丙酸衍生物 |
| WO2002046146A1 (fr) * | 2000-12-05 | 2002-06-13 | Kyorin Pharmaceutical Co., Ltd. | Derives d'acide carboxylique substitues |
| CN102083429A (zh) * | 2008-04-24 | 2011-06-01 | 新联基因股份公司 | Ido抑制剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015022462A8 (pt) | 2019-11-26 |
| BR112015022462A2 (pt) | 2017-07-18 |
| EA201591823A1 (ru) | 2016-01-29 |
| JP6313415B2 (ja) | 2018-04-18 |
| ES2733546T3 (es) | 2019-11-29 |
| CA2907178A1 (en) | 2014-09-25 |
| WO2014150646A1 (en) | 2014-09-25 |
| PE20151594A1 (es) | 2015-11-19 |
| JP2016518324A (ja) | 2016-06-23 |
| EP2970114B1 (en) | 2019-05-15 |
| CN105324362A (zh) | 2016-02-10 |
| US20160060237A1 (en) | 2016-03-03 |
| HK1220442A1 (zh) | 2017-05-05 |
| PH12015502028A1 (en) | 2016-01-18 |
| AU2014235816B2 (en) | 2018-05-17 |
| EA028424B1 (ru) | 2017-11-30 |
| MA38483A1 (fr) | 2018-02-28 |
| SG11201506920QA (en) | 2015-09-29 |
| AU2014235816A1 (en) | 2015-11-05 |
| ZA201506796B (en) | 2017-08-30 |
| EP2970114A1 (en) | 2016-01-20 |
| US9624188B2 (en) | 2017-04-18 |
| IL241321A0 (en) | 2015-11-30 |
| KR20150129010A (ko) | 2015-11-18 |
| MX2015012056A (es) | 2015-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105324362B (zh) | Ido抑制剂 | |
| CN105209443B (zh) | 吲哚胺2,3-双加氧酶(ido)抑制剂 | |
| JP6478991B2 (ja) | Ｉｄｏ阻害剤 | |
| US7030118B2 (en) | Pyrrolotriazinone compounds and their use to treat diseases | |
| ES2719327T3 (es) | Inhibidores de IDO | |
| CA3088858A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| JP2018525341A (ja) | Ｉｄｏ阻害剤 | |
| AU2020311925A1 (en) | Peptide conjugates of microtubule-targeting agents as therapeutics | |
| CN107698594A (zh) | 吲哚胺2，3‑双加氧酶抑制剂及其在药学中的用途 | |
| CN111902400B (zh) | 芳香族衍生物其制备方法和医学用途 | |
| CA3222404A1 (en) | Heterocyclic jak inhibitor | |
| WO2022155172A1 (en) | Peptide conjugates of therapeutics | |
| CN108424415A (zh) | 一类吲哚胺2，3-双加氧酶调节化合物及其在药学中的用途 | |
| CN108424414A (zh) | 一类含杂环的吲哚胺2，3-双加氧酶调节化合物及其在药学中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170524 Termination date: 20200312 |